Sanara MedTech (SMTI) Q4 2025 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Mon, May 4, 2026 astatine 11:53 AM CDT 24 min read

Image source: The Motley Fool.

DATE

Tuesday, March 24, 2026 astatine 8 a.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Seth Yon

• Chief Financial Officer — Elizabeth Taylor

Full Conference Call Transcript

Seth Yon: Thanks, operator, and welcome, everyone, to our 4th fourth and afloat twelvemonth 2025 net call. Let maine outline the docket for today's call. I'll statesman by reviewing respective cardinal fiscal accomplishments for the afloat twelvemonth 2025. I'll past sermon our 4th fourth nett gross show arsenic good arsenic our commercialized execution crossed the 3 cardinal initiatives, our commercialized strategy. After this, I'll supply an update connected a fewer different prime areas of operational advancement successful the quarter. Elizabeth volition screen our 4th fourth fiscal results successful further item and reappraisal our afloat twelvemonth nett gross guidance for 2026, which we reaffirmed successful our net merchandise today.

I'll past reason our remarks with immoderate thoughts connected our positioning arsenic we participate 2026, our strategical priorities for the twelvemonth and our outlook earlier we unfastened the telephone for questions. With that said, let's get started. Looking backmost astatine our fiscal show for the afloat twelvemonth 2025, I'd similar to item respective cardinal accomplishments to show the important advancement we've made arsenic an organization. First, we exceeded $100 cardinal of nett gross for the archetypal clip successful our company's history. Specifically, we generated $103.1 cardinal of nett gross for the afloat twelvemonth 2025, representing maturation of 19% year-over-year.

Importantly, we accomplished this awesome show portion maintaining the size of our tract income squad with 40 representatives astatine the extremity of 2025. Our tract income headcount astatine the extremity of 2025 was fundamentally unchanged compared to the extremity of 2024, 2023 and 2022. Our show demonstrates the spot of our hybrid commercialized model, which includes some tract income reps and a increasing web of autarkic distributor partners. Together, they rise consciousness of our products and amended prospective surgeon customers connected their benefits and objective applications. Second, we drove important improvements successful our profitability illustration connected a year-over-year basis.

Specifically, we expanded our gross margins by astir 200 ground points to 93% for the afloat twelvemonth 2025 and demonstrated notable operating leverage. We yet achieved a $1.5 cardinal oregon 80% simplification successful nett nonaccomplishment from continuing operations and a $7.9 cardinal oregon 86% betterment successful adjusted EBITDA, resulting successful $17 cardinal for the afloat twelvemonth 2025. Third, this performance, coupled with improvements successful our moving superior management, yet enabled america to make $6.8 cardinal of currency provided by operations for the afloat twelvemonth 2025. This compares to $24,000 of currency utilized successful operations for the afloat twelvemonth 2024.